Olema Pharmaceuticals, Inc. (OLMA)
Nasdaq: OLMA · Pharmaceutical Preparations · San Francisco, CA · filing with the SEC since 2018
Who owns Olema Pharmaceuticals, Inc.
As filed with the SECHolders of 5% or more
7
Fmr LLC holds 13.8% of COMMON STOCK, as its SCHEDULE 13G/A filed Aug 6, 2026 says.
Directors and officers
27
report now, of 32 people on the record since 2020. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 7 named at left.
Holders of 5% or moreshare of the class, as filed
Fmr LLC
SCHEDULE 13G/A · filed Aug 6, 2026 · COMMON STOCK · 12.5% in Mar 6, 2026
Paradigm BioCapital Advisors LP
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock, $0.0001 par value per share
Bvf Partners L P/il
SCHEDULE 13D/A · filed Oct 16, 2026 · Common Stock, par value $0.0001 per share
Janus Henderson Group PLC
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock · 8.4% in Feb 17, 2026
Bain Capital Life Sciences Opportunities IV, L.P.
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, $0.0001 par value per share · 9.99% in Feb 17, 2026
Blackrock, Inc.
SCHEDULE 13G/A · filed Jul 29, 2026 · Common Stock
Raymond Debbane
SCHEDULE 13G · filed Mar 20, 2026 · Common Stock, par value $0.0001 per share
Logos Global Management LP
SCHEDULE 13D/A · filed May 13, 2025 · Common Stock · reported falling below 5%
Point72 Asset Management, L.P.
SCHEDULE 13G/A · filed May 15, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%
Deep Track Capital, LP
SCHEDULE 13G/A · filed Feb 13, 2026 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 5.04% in May 15, 2025
What OLMA reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Cowen and Company, L L C
An entity · legal entity · owns, named in the 10-K filed Mar 16, 2026
2 subsidiaries in 2 countries, from the list filed with the 10-K filed Mar 16, 2026.
Insider tradesForm 4
25sales
0purchases
0sales on a scheduled plan
6people selling
$24.7Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window6 of 46 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Clark Ian T | director | 3 | $7.9M | 0 | 0 | $0 |
| Zojwalla Naseem | CHIEF MEDICAL OFFICER | 4 | $7.5M | 0 | 0 | $0 |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | 8 | $4.7M | 0 | 0 | $0 |
| Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | 2 | $3.0M | 0 | 0 | $0 |
| Mitchell Shawnte | CHIEF LEGAL OFFICER | 3 | $1.0M | 0 | 0 | $0 |
| Harmon Cyrus | Chief Research Officer | 5 | $700,000 | 0 | 0 | $0 |